The Department of Biotechnology (DBT) has invited involve proposals under the Coalition for Epidemic Preparedness Innovations (CEPI) on Complementary clinical trials for Covid-19 vaccines and rapid response to clinical development gaps.
The purpose of the new call is to supply critical evidence to deal with current gaps in our clinical knowledge of vaccine performance both now and within the long-term, so as to expand access to Covid-19 vaccines as a part of the worldwide vaccination rollout.
The programmes supported through this call could advance current Covid-19 immunisation efforts through providing data on demographics and age-groups which will not currently be eligible to receive doses of Covid-19 vaccines, like pregnant and lactating women, infants and youngsters , and people who are immunocompromised. If trial assessments indicate Covid-19 vaccines are safe, tolerable and produce an immune reaction in such populations, data could inform and influence current vaccination rollout strategies round the world to expand access to those key groups.
Clinical studies in some age-groups like infants and youngsters could also provide important information on the dimensions of vaccine dose needed to be impactful. additionally , transmission studies, whereby research is conducted watching the impact of a Covid-19 vaccine to stop the virus from ‘spreading’ from one individual to a different , would be supported as sufficient evidence isn’t yet available.
It also include to supply data that would guide future vaccination efforts, for instance whether booster doses could also be necessary; the length of your time a vaccine remains effective (the degree to which a vaccine prevents disease, and possibly also transmission); and therefore the potential impact of novel variants on vaccine performance.
Up to US$ 140 million, contingent upon the supply of funds, is to be made available to scientific groups worldwide to hold out the supporting research on Covid-19 vaccines either already available to populations in some countries under ‘emergency use approval’ or ‘conditional licensure’ or similar, or currently in clinical development.
DBT solicits participation of Indian scientists/vaccine developers are eligible for the proposals.
The last date for submitting the proposals is May 28, 2021.